Since transfection of dendritic cells (DC) plays a key role in DNA vaccination, in vivo expansion of DC might be a tool to increase vaccine efficacy. We asked whether Fms-like tyrosine kinase-3 ligand (Flt-3L), a growth factor for DC, can be used as an adjuvant for DNA vaccination. Betagalactosidase (b-gal) was used as a model antigen in C57BL/6 mice. Mice were immunized i.m. with DNA coding for b-gal with or without additional injection of Flt-3L. In both cases, antigen-specific CD4 þ and CD8 þ T cells were detectable after vaccination. Compared with DNA alone, additional administration of Flt-3L led to a significant increase in the antigen-specific proliferative response. However, increased cytotoxicity by T cells was not observed. The cytokines secreted by splenocytes of immunized mice upon in vitro stimulation with antigen had a TH2 profile. Humoral responses against b-gal preferentially consisted of IgG1 antibodies. Analysis of DC from Flt-3L-treated mice revealed an immature phenotype with low or absent expression levels of CD80, CD86 and CD40. We conclude that Flt-3L does not generally skew immune responses towards a TH1 type. More likely, factors determined by the antigen and/or the vaccination procedure itself are crucial for the resulting type of immune response. Flt-3L -under circumstances such as the one we have investigated -can also lead to suppression of TH1 T cell immunity, possibly by expansion of immature/ unactivated DC.
Introduction
Genetic immunization using naked DNA is a promising approach both for vaccination against infectious diseases and against tumor-associated antigens in cancer patients. Vaccination with DNA coding for a whole tumor antigen offers several potential advantages over peptide vaccination: (1) multiple MHC class I and class II epitopes can be introduced into antigen-presenting cells (APC) and subsequently be presented to CD8 þ and CD4 þ T cells, (2) preferential MHC class I presentation of the antigen can be achieved, since antigen is processed in the 'endogenous' pathway and (3) CpG sequences in the DNA have strong immunostimulatory capacity and can thereby serve as 'natural' adjuvant. Dendritic cells (DC) play a key role in the induction of an antigen-specific Tcell response after DNA vaccination. 1 Although DNA vaccines are able to elicit both humoral and cellular immune responses, 2 genetic immunization against tumors has often been hampered by the failure of the vaccine to elicit a cytotoxic T-cell response strong enough to induce tumor rejection. Coexpression of cytokines and other immunomodulatory molecules has been described as a strategy to overcome this problem. 3 Since transfection of DC plays a key role in DNA vaccination, in vivo expansion of DC might be a strategy to amplify antitumor responses induced by DNA immunization.
Flt-3 (Fms-like tyrosine kinase 3) is a member of the class III receptor tyrosine kinase family. In normal bone marrow, Flt-3 expression is restricted mainly to early progenitor cells of myeloid and B-cell origin. Flt-3 ligand (Flt-3L) is a type I transmembrane protein expressed in bone marrow stroma cells and cells of myeloid, B-and T-cell origin. 4 Flt-3L induces massive expansion of both myeloid and lymphoid DC in mice and in humans. 5, 6 We asked whether Flt-3L-induced expansion of DC is able to amplify the immune response against a model antigen (b-galactosidase, b-gal) upon DNA vaccination.
Results
In vivo expansion of DC in C57BL/6 mice by Flt-3L
In order to achieve in vivo expansion of DC, C57BL/6 mice were injected s.c. with Flt-3L. The treatment protocol is shown in Figure 1 .
After 12 days of subcutaneous Flt-3L administration, spleens of C57BL/6 mice showed a significant enlargement and the number of splenocytes harvested was increased by a factor 3-4 compared with mice injected with PBS alone. In the spleens of Flt-3L-treated animals, there was a substantial expansion of CD11c þ MHC class II þ DC as shown by immunohistochemical staining and by flow-cytometric analysis (Figures 2 and 3) . On FACS analysis, splenocytes contained both myeloid CD11c þ CD11b þ DC and lymphoid CD11c þ CD11bÀ DC (Figure 3d ) as described previously. 5 Effect of Flt-3L on the proliferative immune response
In initial experiments, we showed that two i.m. immunizations with plasmid DNA coding for b-gal are able to induce an antigen-specific immune response as measured in a standard 5 days [ 3 H]thymidine assay. In animals injected with mock vector (pcDNA3), no significant immune response was detectable (data not shown). We then compared vaccination efficacy after the injection of DNA (b-gal) plus Flt-3L, DNA (b-gal) alone, Flt-3L alone or PBS by using splenocytes of immunized and control mice in a standard [ 3 H]thymidine proliferation assay, with b-gal as an antigen and without any further in vitro restimulation (Figure 4 ). The vaccination was performed according to the schedule shown in Figure 1 . Mice immunized with DNA (b-gal) alone had a weak but significant antigen-specific proliferative response against b-gal (stimulation index approximately 2). Figure 4 shows that coadministration of Flt-3L during DNA vaccination leads to an increase of the b-gal-specific proliferative response. In our experiments, the proliferative response was increased by a factor 3-4 compared with DNA alone. Interestingly, Flt-3L alone also induced a slight increase compared with DNA alone.
Effect of Flt-3L on the cytotoxic T-cell response against b-gal-expressing target cells
After two immunizations with DNA coding for b-gal according to the schedule mentioned above (Figure 1) , splenocytes of the mice were restimulated in vitro for 5 days with an H2-Kb-restricted b-gal peptide (DA-PIYTNV), b-gal protein-or b-gal-transfected syngeneic tumor cells in the presence of IL-7. In none of these Figure 1 Experimental setting: mice were injected twice i.m. with 100 mg pcDNA3-lacZ on days 7 and 28. Flt-3L was administered at a dosage of 10 mg/day from day 1 until day 12 and from day 22 until day 33. On day 42, immunological assays were performed using splenocytes from the different groups of mice treated with pcDNA3-lacZ þ Flt-3L, pcDNA3-lacZ, Flt-3L alone or PBS. Flt-3L as adjuvant for DNA vaccination J Westermann et al experiments, significant specific cytotoxicity against bgal-expressing syngeneic target cells was detectable in standard 51 Cr release assays (specific cytotoxicity at an effector:target ratio of 80:1: PBS 3%, DNA (b-gal) 6%, Flt-3L 5%, DNA (b-gal) þ Flt-3L 2%).
Analysis of phenotype and cytokine profile of T cells after DNA vaccination against b-gal
In immunized mice, the presence of antigen-specific CD4 þ and CD8 þ T cells was analyzed by means of a cytokine secretion assay (MACS g-interferon (g-IFN) secretion assay). After immunization with DNA (b-gal) alone or with DNA (b-gal) plus Flt-3L, b-gal-specific T cells were found in the spleen of the animals. In control animals, which had been injected with PBS or Flt-3L alone, no b-gal reactive T cells were detected ( Figure 5 ). Since both CD8 þ and CD4 þ b-gal-specific T cells were present, we continued to study phenotype and cytokine secretion profile of T cells after vaccination. We first analyzed the phenotype of in vitro restimulated CD3 þ CD8 þ splenocytes after vaccination using anti-CD44 and anti-CD62L antibodies as described previously. 7 Although CD3 þ CD8 þ antigen-specific T cells were present, most of these cells did not have the phenotype of activated CTL (CD44 þ CD62LÀ), neither in mice immunized with DNA alone nor in those that had been additionally injected with Flt-3L. The proportion of CD44 þ CD62LÀ activated CTL in immunized mice was only slightly increased above the background level of unimmunized animals ( Figure 6 ). Since CTL were not found even after in vitro restimulation, we evaluated secretion of different cytokines in these splenocyte cultures after 5 days in vitro restimulation with the H2-Kb-restricted b-gal peptide and IL-7. Cytokines in the supernatants were determined immediately before performing 51 Cr release cytotoxicity assays: ELISAs for g-IFN, IL-2, IL-12, IL-4 and IL-10 showed that neither DNA vaccination alone nor additional coadministration of Flt-3L had induced T cells, 
Phenotypic analysis of DC expanded in vivo by Flt-3L
Since our findings showed that Flt-3L coadministration failed to elicit a TH1T-cell response against b-gal, we Figure 6 Phenotype of CD3 þ CD8 þ T cells in the spleen: CD3 þ CD8 þ T cells from the spleen of immunized and unimmunized mice were analyzed by flow cytometry for CD44 and CD62L expression. By this flow-cytometric analysis, the following phenotypes could be identified in the CD3 þ CD8 þ T-cell population: CD62L þ CD44À (naive T cells), CD62L þ CD44 þ (memory T cells) and CD62LÀCD44 þ (activated CTL). 7 Coadministration of Flt-3L was not able to induce a significant increase of CTL, n ¼ 2 for each group of mice. Data are representative of two independent experiments. Flt-3L as adjuvant for DNA vaccination J Westermann et al performed a further characterization of the phenotype and maturation status of DC expanded by Flt-3L. Splenocytes were studied by flow cytometry after 12 days injection with Flt-3L. We found that Flt-3L expanded DCs have an immature phenotype with CD80À, CD86À and CD40À expression being very low or absent ( Figure 9 ). However, after culturing these cells overnight in the presence of LPS, a fully mature phenotype with high expression levels of CD80, CD86 and CD40 could be achieved. In comparison with bone marrow-derived DC generated in the presence of GM-CSF as described previously, 8 we could demonstrate that Flt-3L-induced splenic DC are able -after the addition of LPS as a maturation stimulus -to develop a mature phenotype with expression levels of accessory molecules being comparable with bone marrow DC generated in the presence of GM-CSF (Figure 9 ).
Discussion
DC-based immunization against tumors has shown promising results both in animal studies and in initial clinical trials in cancer patients. 9 Since vaccination using ex vivo generated DC is a cost-and time-intensive procedure and many questions with regard to in vitro generation, dose of antigen and time of application are still highly debatable, alternative strategies that facilitate treatment of larger groups of patients are of great interest.
DNA vaccines have the potential for application as a 'general vaccine' against putative tumor antigens across HLA barriers in a large cohort of patients. Since transfection of DC is a crucial step in genetic immunization, 1, [10] [11] [12] in vivo expansion of DC by Flt-3L could possibly circumvent the laborious large-scale ex vivo generation and ex vivo modification of DC for vaccination trials.
We used b-gal as a model antigen, since it is well established and several immunogenic MHC-restricted peptides have been described. Furthermore, humoral and cellular immune responses have been reported after DNA immunization against b-gal. 13, 14 The DNA vaccine was injected at a time (day 7) when DC had already been substantially expanded in vivo by Flt-3L, 5 Flt-3L application was then continued for another 5 days in order to achieve a high number of in vivo transfected DC.
Our results confirm in vivo expansion of myeloid and lymphoid DC after s.c. administration of Flt-3L as had been reported previously. 5 Analysis of antigen-specific T cells by g-IFN secretion assays clearly demonstrated that vaccination with pcDNA3(lacZ) with or without coadministration of Flt-3L-induced b-gal-specific CD4 þ and CD8 þ T cells. Splenocytes of animals that had been coinjected with Flt-3L showed a three-to four-fold increase in the b-gal-specific response. Surprisingly, splenocytes of mice that had been injected with Flt-3L alone showed an antigen-specific proliferative immune response higher than in animals immunized with pcDNA3(lacZ) alone. It can be assumed that this is an in vitro effect due to a higher proportion of DC in the spleen of these Flt-3L-treated mice. In addition, this could also be due to a higher level of Flt-3L-induced cytokine release by splenocytes as has been reported previously. 15 So amplification of the proliferative response in mice coinjected with pcDNA3(lacZ) and Flt-3L can be ascribed in part to nonantigen-specific factors, but in addition our data indicate that a higher number of antigen-specific splenocytes had been induced in these animals compared with pcDNA3(lacZ) or Flt-3L alone.
Unexpectedly, despite augmentation of the proliferative immune response by Flt-3L, no antigen-specific CTL activity was found in animals coinjected with Flt-3L: neither pcDNA3(lacZ)-nor pcDNA3(lacZ)/Flt-3L-injected mice showed significant b-gal-specific T-cell cytotoxicity. A possible explanation for the lack of CTL response despite the presence of antigen-specific CD8 þ T cells is the cytokine milieu in the splenocyte cultures after 5 days of in vitro restimulation with b-gal peptide and IL-7. The low levels of g-IFN and IL-12 and the increase in IL-4 and IL-10 indicate a TH2-type response upon vaccination with pcDNA3(lacZ) as compared with unimmunized animals. In animals coinjected with pcDNA3(lacZ) and Flt-3L, the TH2 cytokine profile was Flt-3L as adjuvant for DNA vaccination J Westermann et al even more pronounced. These data suggest that Flt-3L does not per se shift the immune response towards a TH2 phenotype but is rather increasing the preferential TH2 response elicited by the vaccine itself, and it is not able to skew the T-cell response. Rather Flt-3L seems to augment the TH2 polarization of the vaccine. The TH2 profile was additionally confirmed by a preferential IgG1 antibody production in mice treated with pcDNA3(lacZ) and Flt-3L. DCs play an important role for TH1/TH2 polarization of immune responses. Our in vivo generated DC showed an immature phenotype with low or absent surface expression of costimulatory molecules such as CD80, CD86 and CD40. Only after exposure to a maturation stimulus they were able to differentiate into fully mature DC. Antigen presentation by DC with such an immature phenotype has been previously described as being tolerogenic rather than immunogenic. 16 In the literature, conflicting data have been reported concerning the effect of Flt-3L on vaccination. Initial animal studies using different tumor models showed that Flt-3L is able to protect mice from a subsequent tumor challenge. [17] [18] [19] [20] [21] However, in some of these studies a major contribution to antitumor response may have been provided by NK cells. 18, 22, 23 Pulendran et al 24 reported prevention of peripheral tolerance against vaccination with chicken ovalbumin when Flt-3L was coadministered. However, in this study an expansion of CD86 þ DC was reported that was not found in our experiments and also by others, so that additional maturation signals can be assumed in their experimental system, which indeed was dependent on CD40-CD40L interaction. Furthermore, Pulendran et al used a T-cell hybridoma specific for OVA that might possibly respond differently to antigenic stimuli than primary T cells. Kim et al 25 showed in a murine colon cancer model that injection of Flt-3L-gene-transduced xenogeneic cells together with tumor lysate and IL-2 can induce antitumor immunity and protection from tumor growth. However, in this model tumor protection by the vaccine was largely dependent on coadministration of IL-2. Parajuli et al 15 reported induction of a type 1 T-cell response after coadministration of Flt-3L with sequential immunization against p53 using adenovirus-p53 and plasmid-p53. In this study, the vaccine itself already induced a type 1 T-cell response, which was amplified by Flt-3L. Interestingly, these authors could also hardly detect functional CTL, although g-IFN-secreting T cells were present in ELISpot assays.
On the other hand, some vaccination studies found a lack of effect or even an inhibitory influence of Flt-3L on the immune response in mice. 26, 27 A pilot study in patients with her2/neu-expressing prostate cancer did not show significant T-cell responses using Flt-3L as adjuvant for her2/neu peptide vaccination. 28 Viney et al 29 could demonstrate that Flt-3L is able to enhance induction of oral tolerance to ovalbumin in mice.
Yunosov et al 30 showed that Flt-3L promotes engraftment of allogeneic hematopoietic stem cells without graftversus-host disease.
Ciavarra et al 31 interestingly reported recruitment of tumor-infiltrating DC by Flt-3L in a mouse model of prostate cancer. However, DC progressively lost their MHC class II expression, which could not be prevented by maturation stimuli such as CD40-L. In this model, the tumor microenvironment lead to substantial functional deficiency of tumor-infiltrating T cells.
Our hypothesis is that Flt-3L per se is neither able to determine the outcome of vaccination in terms of immunity or tolerance nor is it able to induce TH polarization. More likely, further signals provided by the vaccination procedure itself decide whether the outcome is immunity or tolerance, and can skew the immune response towards a TH1 or TH2 type. Some of these additional signals trigger IL-12 production and induce TH1 polarization, others fail to do so, thereby leading to TH2 responses. In addition, an exhaustion of cytokine production has been described and may also influence TH polarization by reverting TH1 cells into TH2 or nonpolarized T cells. 32 These additional signals may be related to the ability of the antigen formulation to induce DC maturation, but dosage and route of presentation (MHC-I versus MHC-II) can also influence TH polarization. [33] [34] [35] [36] Moreover, the amount of CpG sequences in DNA vaccines can influence via toll-like receptors (TLR) whether a TH1 or TH2 T cell response is generated. 33 It appears that the amount of immunostimulatory CpG sequences in our plasmid DNA is not sufficient to induce TH1 polarization. Indeed, coadministration of antigen with immunostimulatory, CpG-rich DNA and Flt-3L can induce therapeutic immunity. 37 Therefore, the use of CpG-rich DNA can generally be recommended for tumor vaccination.
Our results are in line with the increasing evidence that factors like the cytokine milieu, the T cell:DC ratio, the antigen dose and additional (microbial) stimuli are more important for the functional outcome of a T-cell response than the primary DC subtype involved. 36, 38 This view is also supported by a recent study by Mosca et al, 39 which suggests that Flt-3L expanded DC can only stimulate allogeneic T cells to secrete g-IFN after having been exposed to additional maturation signals. In conclusion, we feel that the use of Flt-3L alone cannot be recommended for immunological antitumor therapy, but the use of other cytokines and/or immunomodulatory molecules together with Flt-3L might offer attractive perspectives for immunotherapy.
Material and methods

Animals
Female 8-to 12-week-old C57BL/6 (H-2k b ) mice were purchased from Charles River (Wilmington, MA, USA) and maintained in our animal facility under standard conditions.
Experiments were approved by local authorities (LAGeTSi, Berlin), which supervise animal studies.
Preparation of plasmid DNA
PcDNA3 mock vector and pcDNA3-LacZ (LacZ) containing the LacZ gene, coding for b-gal, under the control of a CMV promoter were used for vaccination experiments. The plasmids were amplified in Escherichia coli X1-blue strain (Stratagene) and purified using the EndoFree Giga Kit (Qiagen) according to the manufacturer's instructions. 
Immunization protocol
Mice were injected twice i.m. with 100 mg pcDNA3-lacZ on days 7 and 28. rh-Flt-3 Ligand (kindly provided by Dr Kathleen Picha, Amgen Inc., Thousand Oaks, CA, USA) was administered at a dosage of 10 mg/day from day 1 until day 12 and from day 22 until day 33, so that Flt-3L was injected for a period of 12 days around each vaccination (Figure 1 ). Owing to the large amount of Flt-3L necessary for the treatment (240 mg/mouse), each treatment group consisted of two mice.
Preparation of splenocytes
On day 42 (14 days after the last immunization), mice were killed, spleens were aseptically removed and a single-cell suspension was generated in RPMI-1640 (Gibco, BRL) supplemented with 100 IU/ml penicillin, 100 mg/ml streptomycin (Gibco), 2 mM L-glutamine (Gibco) and 10% fetal calf serum (FCS) (Gibco). Erythrocytes were lysed by using erythrocyte lysis buffer (EDTA þ NH 4 CL þ Na 2 CO 3 ). Finally, splenocytes were washed twice in RPMI-1640 and subsequently used for immunological assays.
Preparation of DC Splenic DC from mice treated with Flt-3L. Splenic DC were generated as described previously (Current Protocols in Immunology, Vol. 1; 3.7.2). Briefly, freshly prepared splenocytes were resuspended in 10 ml RPMI-1640 containing 100 IU/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine, 50 mM 2-mercaptoethanol (Gibco) and 10% FCS ( ¼ complete medium), seeded in 10 mm Petri dishes (TPP, Aindling-Arnhofen, Germany) and incubated at 371C for 2-3 h. Nonadherent cells were discarded and cells were cultured in complete medium containing 10 ng/ml GM-CSF (PeproTech, London, UK) and 25 ng/ml LPS (Sigma, Tan & Kirchen, Germany) overnight. On the next day, cells were collected and used for FACS analysis.
Bone marrow-derived DCs. Bone marow cells were prepared from femur and tibia of mice and then resuspended in 12 ml complete medium, seeded in sixwell plates (Nunc) and incubated at 371C for 2-3 h. Nonadherent cells were subsequently distributed into new plates and cultured in complete medium containing 10 ng/ml murine GM-CSF. On the next day, nonadherent cells were carefully removed. Adherent cells were continuously cultured in GM-CSF containing complete medium. On day 2, nonadherent cells in the culture were discarded again. On days 5 and 7, 1 ml of medium containing 10 ng/ml GM-CSF was added. In order to induce final maturation, LPS (25 ng/ml) was added on day 7. On day 8, mature DCs (about 80-90% nonadherent cells) were collected and used for FACS analysis.
Phenotypic analysis of DC and T cells by flow cytometry
Direct immunofluorescence cell staining was performed using the following antibodies: CD11c-PE, CD44-PE, CD40-FITC, CD80-FITC, CD86-FITC, CD11b-FITC, A-Ib-FITC, CD3-FITC, CD8-PerCP and CD62L-APC (all Pharmingen, Heidelberg, Germany). For the analysis of DC, cells were blocked with purified anti-CD32 and anti-CD64 antibodies (Pharmingen) immediately before the staining procedure. Cells (10 000) were analyzed using a FACScan (Beckton-Dickinson, Mountain view, CA, USA).
Immunohistochemistry
The spleen samples of mice were placed in embedding medium (Tissue Tek OTC compound, SAKURA, Giessen, Germany), snap-frozen in liquid nitrogen and stored at À801C. From these frozen spleen samples cryostat sections were prepared and fixed in acetone. Cryostat sections were incubated subsequently with (1) blocking buffer (PBS containing 3% BSA, Sigma), (2) biotinylated anti-A-Ib and anti-CD11c-FITC or appropiate IgG isotype control (all Pharmingen), (3) streptavidin peroxidase-(Sigma) and anti-alkaline phosphatase-FITC (Roche Applied Science, Mannheim, Germany), (4) peroxidase substrate (DAB, Sigma) and fast Red substrate (Sigma) and (5) 'cytology' solution (Merck) to stain cell nuclei. Stained cryosections were photographed using a fluorescence microscope (Olympus).
Proliferative T-cell responses
Triplicate of 10 5 splenocytes were cultured in complete medium with or without 5 mg/ml of b-gal protein (Roche Applied Science) using 96-well round bottom plates (Nunc). On day 4, 
Chromium release assays
At 2 weeks after the second DNA vaccination (day 42), splenocytes from each group of immunized and unimmunized mice were pooled and restimulated in vitro for 5 days in complete medium in the presence of 5 mg/ml bgal peptide (DAPIYTNV, Wita GmbH, Berlin, Germany) and 10 U/ml IL-7 (Peprotech, London, UK). The cell lines EL-4 or MC-57 pulsed with 10 mg/ml b-gal peptide and labeled with 51 Cr were used as target cells in triplicate. On day 6, effector and target cells were coincubated for 4 h at 371C. After that time, 50 ml of culture supernatant were transferred into lumina plates (Packard) and evaluated by counter (Top Count). The percent specific cytotoxicity was calculated using the formula: % specific cytotoxicity ¼ 100 Â (experimental releaseÀspontaneous release/maximum releaseÀspontaneous release).
IFN-g secretion assay
Detection of antigen-specific CD4 þ and CD8 þ T cells was performed using a g-IFN secretion assay (Miltenyi, Bergisch-Gladbach, Germany). Briefly, splenocytes from each group of mice were pooled and 2 Â 10 7 splenocytes/ group were restimulated overnight in complete medium with or without 10 mg/ml b-gal protein in 24-well plates (Nunc) at 371C. g-IFN-secreting antigen-specific T cells were then enriched by a Macs column (Miltenyi), stained with anti-CD4 or anti-CD8 antibody (both Pharmingen) and quantified by FACS analysis according to the manufacturer's instructions. Dead cells were excluded by using propidium iodide.
ELISA
Antibody responses were analyzed in serum samples by ELISA. Briefly, 96-well microtiter plates (Nunc Immuno MaxiSorp plates, Life Technology GmbH, Karlsruhe, Germany) were coated overnight at 41C with 100 ml of a Plates were washed once with washing buffer (PBS þ 0.05% Tween-20, TPBS) and then treated overnight with 250 ml of blocking buffer (0.5% BSA, fraction V, Roth, in washing buffer þ 0.1% sodium acid). After washing twice, plates were incubated at RT for 1 h with 100 ml of serial dilutions of serum samples in TPBS (1:30, 1:60, 1:120 and 1:240). After washing four times with TPBS, plates were incubated for 1 h with 100 ml of a 1:1000 dilution of biotinylated anti-mouse IgG1, IgG2a, IgG2b, IgG3 (Pharmingen) in TPBS. Hereafter, plates were washed four times with TPBS and incubated with 100 ml of a 1:1000 dilution of streptavidin-AKP (Pharmingen). After 0.5-1 h incubation at RT, plates were thoroughly washed and 200 ml MUP (Sigma) was added in each well. After 0.5-1 h at RT, photometric analysis was performed using a multilabel plate reader (Perkin Elmer, Boston, MA, USA). Analysis of the cytokine secretion in cell culture supernatants was performed with pooled splenocytes from each group of mice using an ELISA for IL-2, IL-4, IL-10, IL-12 and g-IFN (Pharmingen) according to the manufacturer's instructions. All analyses were performed in triplicate.
